Media release

From: Wiley

SARS-CoV-2 SEROPREVALENCE IN CHILDREN, EARLY 2021

EMBARGOED UNTIL 12:01am Monday 13 June 2022

THE seroprevalence of SARS-CoV-2-specific antibodies in children was between 0.21% and
0.42% early in 2021, according to research published today by the Medical Journal of
Australia.

The “seroprevalence” of a sample of people is the proportion of people tested who had
detectable antibodies against SARS-CoV-2 in their blood serum. This is important because it
provides a way of estimating the fraction of a population that has been infected with the virus.

In Australia, the other way of doing this is relying on RAT or PCR testing during an active
infection, but this undercounts infections because not everyone who is infected will do a test
or report the result, especially as many infections are mild or asymptomatic.

To get a better estimate of how many people have been infected with the virus,
epidemiologists look for sources of blood samples that are broadly representative of the
population of interest. In the past this has been done using blood bank donations or blood
samples obtained for routine clinical care.

The MJA study, led by Dr Archana Koirala, a paediatric infectious diseases physician at the
National Centre for Immunisation Research and Surveillance (NCIRS), and Nepean Hospital,
used blood collected during anaesthesia when children were having elective surgery. The
researchers measured the seroprevalence in their sample of children, then extrapolated this
to the broader population of Australian children.

“SARS-CoV-2-specific antibodies were detected in seven children (5–9 years, one; 10–19
years, six): three in Victoria, three in New South Wales, one in Queensland; three specimens
were also positive in immunofluorescent antibody and microneutralisation assays,” Koirala
and colleagues reported.

“The crude seroprevalence of SARS-CoV-2-specific antibodies was 0.42%. After adjusting for
sensitivity and specificity, estimated seroprevalence using the base case prior distribution for
people aged 0–19 years was 0.23%.

“This corresponds to 13 719 aged 0–19 years in the five mainland states being infected with
SARS-CoV-by early 2021. Using a less conservative prior distribution (greater weight
assigned to lower seroprevalence values), estimated seroprevalence was 0.16%,
corresponding to 9545 infections.”

Apart from the estimate of seroprevalence, Koirala and colleagues also showed the approach
of using blood samples taken while children were under anaesthesia for elective surgery was
useful and could be used for tracking the COVID-19 pandemic in the future.

“Our opportunistic, consent-based method of blood sampling was highly effective in
achieving the required sample size for analysis and could be used for future seroepidemiological monitoring of SARS-CoV-2 in children, especially after the surge in infections from mid-2021,” they concluded.

All MJA media releases are open access and can be found at:
https://www.mja.com.au/journal/media